BIOMAT Database Logo BIOMAT Database Logo

Administration of dazoxiben, a selective thromboxane synthetase inhibitor, in the adult respiratory distress syndrome. 1985

M Leeman, and J M Boeynaems, and J P Degaute, and J L Vincent, and R J Kahn

Experimental studies suggest that thromboxane A2 could play a role in the pulmonary hypertension of the adult respiratory distress syndrome (ARDS). We therefore investigated the hemodynamic and gasometric effects of dazoxiben, a selective thromboxane synthetase inhibitor, in seven patients who had developed ARDS. The patients were studied for 120 minutes after a single intravenous bolus of 1.5 mg of dazoxiben per kilogram of body weight. During this period, there was no change in pulmonary hemodynamics, a moderate increase in arterial oxygen pressure, and a slight decrease in venous admixture. Therefore, administration of dazoxiben in patients with ARDS does not decrease pulmonary hypertension. This study does not support the role of thromboxane A2 as an important mediator in pulmonary hypertension in human ARDS, at least once the syndrome has been recognized.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D011652 Pulmonary Circulation The circulation of the BLOOD through the LUNGS. Pulmonary Blood Flow,Respiratory Circulation,Circulation, Pulmonary,Circulation, Respiratory,Blood Flow, Pulmonary,Flow, Pulmonary Blood,Pulmonary Blood Flows
D012128 Respiratory Distress Syndrome A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA. ARDS, Human,Acute Respiratory Distress Syndrome,Adult Respiratory Distress Syndrome,Pediatric Respiratory Distress Syndrome,Respiratory Distress Syndrome, Acute,Respiratory Distress Syndrome, Adult,Respiratory Distress Syndrome, Pediatric,Shock Lung,Distress Syndrome, Respiratory,Distress Syndromes, Respiratory,Human ARDS,Lung, Shock,Respiratory Distress Syndromes,Syndrome, Respiratory Distress
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females

Related Publications

M Leeman, and J M Boeynaems, and J P Degaute, and J L Vincent, and R J Kahn
Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon.
July 1984, Clinical pharmacology and therapeutics,
M Leeman, and J M Boeynaems, and J P Degaute, and J L Vincent, and R J Kahn
Use of a thromboxane synthetase inhibitor, dazoxiben, during haemodialysis.
January 1983, British journal of clinical pharmacology,
M Leeman, and J M Boeynaems, and J P Degaute, and J L Vincent, and R J Kahn
Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial.
January 1983, British journal of clinical pharmacology,
M Leeman, and J M Boeynaems, and J P Degaute, and J L Vincent, and R J Kahn
Dazoxiben in human sepsis and adult respiratory distress syndrome.
April 1985, Clinical pharmacology and therapeutics,
M Leeman, and J M Boeynaems, and J P Degaute, and J L Vincent, and R J Kahn
A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome.
November 1993, Critical care medicine,
M Leeman, and J M Boeynaems, and J P Degaute, and J L Vincent, and R J Kahn
Effects of the selective thromboxane synthetase inhibitor, dazoxiben, on cyclic flow variations in stenosed canine coronary arteries.
January 1983, Transactions of the Association of American Physicians,
M Leeman, and J M Boeynaems, and J P Degaute, and J L Vincent, and R J Kahn
Metabolic protection of the reperfused canine endocardium by the thromboxane synthetase inhibitor, dazoxiben.
July 1988, Prostaglandins, leukotrienes, and essential fatty acids,
M Leeman, and J M Boeynaems, and J P Degaute, and J L Vincent, and R J Kahn
SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
February 1984, Thrombosis and haemostasis,
M Leeman, and J M Boeynaems, and J P Degaute, and J L Vincent, and R J Kahn
Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries.
June 1984, Circulation,
M Leeman, and J M Boeynaems, and J P Degaute, and J L Vincent, and R J Kahn
Imidazole: a selective inhibitor of thromboxane synthetase.
April 1977, Prostaglandins,
Copied contents to your clipboard!